Precisis focuses on international growth: Steven Griffiths appointed VP European Sales

Heidelberg, July 1, 2025 - Precisis, the Heidelberg-based MedTech company specializing in neuromodulation, has appointed Steven Griffiths as Vice President European Sales. With more than 20 years of experience in the medical technology sector, Griffiths will lead the company’s commercial strategy across Europe and support its expansion into new international markets.

Griffiths joins Precisis from Nevro, where he most recently served as Director DACHL. He has also held senior roles at Alcon and ALK. In his new role, he will focus on strengthening the company’s established presence in the UK while driving growth in high-potential markets such as Spain, the Nordics, and the United Arab Emirates.

His appointment comes at a time of strong momentum for the European MedTech sector. In 2023, Germany accounted for 25% of the European market, with 68% of its MedTech revenue generated internationally. Griffiths brings deep expertise in building sales organizations, developing strategic market access, and executing complex commercial structures across Europe.

Precisis’ flagship product, EASEE®—a low invasive brain pacemaker for the treatment of focal epilepsy—has gained recognition for its patient-centered design and technological innovation. With nearly 60% of Europe’s population affected by neurological conditions, the need for advanced therapeutic solutions continues to grow.

“Steven Griffiths brings a rare combination of strategic foresight and operational experience,” said Karl Stoklosa, CEO of Precisis. “His leadership will be instrumental in scaling our impact and making EASEE® accessible to more patients across Europe and beyond.”